Double-blind Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Metastases in Men With Hormone-refractory Prostate Cancer
- Registry ID
- EUCTR2006-000341-19
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE3
- Sponsor
- Amgen Inc
- Start date
- 2006-05-05
- Completion date
- 2012-02-27
- Last update
- 2026-08-16
Conditions
- Treatment of bone metastases in men with hormone- refractory prostate cancer.
- Tratamiento de metástasis óseas en varones con cáncer de próstata hormono-refractario
- Treatment of bone metastases in men with hormone- refractory prostate cancer
- Metastatic castrate-resistant prostate cancer
Summary
To determine if denosumab is non-inferior to zoledronic acid (Zometa) with respect to the first on-study occurrence of a skeletal-related event (SRE) in subjects with hormone-refractory prostate cancer and bone metastases. SRE is defined as pathological fracture (vertebral or nonvertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression.
Locations
- , , Hungary
- , , Spain
- , , Belgium
- , , Austria
- , , UK
- , , Italy
- , , Sweden
- , , Greece
- , , Latvia
- , , Finland
- , , Germany
- , , Netherlands
- , , Denmark
- , , Slovakia
- , , Lithuania
- , , Czechia
- , , Estonia
View on source registry